Drug Trial Radar · NCT01950520
Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
Last checked: Nov 19, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Feb 7, 2014
Primary completion
Dec 17, 2022
Study completion Jun 11, 2024
Sponsor
- Sponsor type
- NIH
- First posted
- Sep 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background: \- Changes in how a person's body burns energy or calories can affect their weight over time. The lowest level of energy the body needs to function is called basal metabolic rate. In the cold, we burn extra energy, even before we start to shiver. This is called non-shivering thermogenesis and it occurs in different types of tissue such as muscle and fat. Researchers want to learn more about this type of energy burning and how it is regulated. They hope this will help treat obesity in the future. Objectives: * Sub-study 1: to better understand how non-shivering thermogenesis works. * Sub-study 2: to measure the effects of anti-obesity drugs on basal metabolic rate. * Sub-study 3: to better understand the effects of mirabegron, a beta-3 adrenergic receptor agonist, on brown fat activity. Eligibility: \- Healthy, lean adult males ages 18 to 35. Design: * Participants will be screened with medical history, physical exam, blood test, and EKG. * For sub-studies 1 and 2: * Participants will receive one X-ray scan. * Each day, all participants will: * Have height and weight measured, and have urine collected. * Spend 4 hours in a temperature-controlled room with furniture, toilet area, phone, and computer. They will wear small non-invasive devices to monitor activity, heart rate, temperature, and shivering. * Walk for 30 minutes. * For sub-study 3: * Participants will receive one DXA scan and up to 4 PET/CT scans and 4 MRIs * Each stay, all participants will: * Have height and weight measured, and have urine collected. * Spend 6 hours in a temperature-controlled room with furniture, toilet area, phone, and computer. They will wear small non-invasive devices to monitor activity, heart rate, temperature, and shivering. * Participants will be compensated for their time and participation at the end of the study
Conditions
- Healthy Volunteers
Interventions
PropranololDrug
Propanolol 160mg, oral, by mouth (Cohort 1 only)
PindololDrug
Pindolol 20mg, oral, by mouth (Cohort 1 only)
DantroleneDrug
Dantrolene 100mg, oral, by mouth (Cohort 1 only)
Magnesium SulfateDrug
Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)
CaffeineDrug
Caffeine 200mg, oral, by mouth (Cohort 2 only)
QsymiaDrug
Qsymia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)
TopiramateDrug
Topiramate 200mg, oral, by mouth (Cohort 2 only)
PhentermineBehavioral
Phentermine 37.5mg, oral, by mouth (Cohort 2 only)
NaltrexoneDrug
Naltrexone 100mg, oral, by mouth (Cohort 2 only)
Mirabegron 50mgDrug
Mirabegron 50mg, oral, by mouth (Cohort 3 only)
Mirabegron 200mgDrug
Mirabegron 200mg, oral, by mouth (Cohort 3 only)
Placebo Cohort 1Drug
Placebo, oral, by mouth (Cohort 1 only)
Placebo Cohort 2Drug
Placebo, oral, by mouth (Cohort 2 only)
Placebo for MirabegronDrug
Placebo for Mirabegron, oral, by mouth (Cohort 3 only)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Resting Energy Expenditure at Low TemperatureTime frame: Cohort 1: Days 1-17
- Resting Energy Expenditure at Low TemperatureTime frame: Cohorts 2: Six one-day overnight inpatient stays over a six to twelve week period.
- Resting Energy Expenditure at Low TemperatureTime frame: Cohort 3: Four one-day overnight inpatient stays over a 12-week period.
- Basal Metabolic RateTime frame: Cohort 1: Days 1-17
- Brown Adipose Tissue Activity (Cohort 3 Only)Time frame: Cohort 3: Four one-day overnight inpatient stays over a 12-week period.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.